ArticleScientific reports2026
Predicting the risk for distant metastasis in hypopharyngeal squamous cell carcinoma and assessing the survival benefit of induction therapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypopharyngeal squamous cell carcinoma (HPSCC) has a poor prognosis due, in large part, to distant metastasis (DM). Although induction therapy (IT) can reduce DM rates, its translation to an overall survival (OS) benefit remains unclear, highlighting the need for tools to identify patients who would benefit most from IT. This study developed a nomogram to predict the risk for DM in patients with HPSCC, and assessed the survival benefit of IT across risk groups. Data from patients obtained from the Surveillance, Epidemiology, and End Results (i.e., "SEER") database (2004-2015) were randomly assigned to 1 of 2 groups at a ratio of 7:3: training; and internal validation. The external validation set comprised patients from 2 medical centers in China. Risk factors were identified using multivariate logistic regression analysis. Male sex, T classification ≥ 2, N classification ≥ 1, and poorer histological grade were independent risk factors for DM. The nomogram demonstrated good discriminative ability, with areas under the receiver operating characteristic curve of 0.702 (95% confidence interval [CI]: 0.669-0.735) in the training set, 0.704 (95% CI: 0.648-0.759) in the internal validation set, and 0.863 (95% CI: 0.804-0.923) in the external validation set. Based on the optimal cut-off value, patients were stratified into high- and low-risk groups. In the high-risk group, patients who received IT exhibited significantly improved OS (hazard ratio [HR] 0.364; 95% CI: 0.165-0.805; P = 0.040) and progression-free survival (PFS; HR 0.420; 95% CI: 0.190-0.928; P = 0.042) compared with those who did not receive IT. There was no significant survival benefit from IT in the low-risk group (OS: HR 0.881; 95% CI: 0.414-1.875, P = 0.095; PFS: HR 0.544 95% CI: 0.182-1.626, P = 0.250). This study constructed and preliminarily validated a nomogram for predicting DM in patients with HPSCC, and may serve as an exploratory tool for screening high-risk patients who are likely to benefit from IT, thereby providing a reference for the design of future prospective intervention trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.